Intrinsic Value
HALOZYME THERAPEUTICS, INC. · HALO
Conservative
More adverse but historically defensible assumptions.
$400.08
Base
The model's central intrinsic-value estimate.
$786.01
Optimistic
More favorable but historically defensible assumptions.
$1,629.87
Scenarios are the same model run under different but historically defensible assumptions. They are not price targets. Where a valuation gap is shown it is a comparison with a recent close, not a forecast return; where the price is stale, no gap is shown at all.
Model confidence: 75%Valuation as of Sep 21, 2026Latest filing used Feb 17, 2026
Confidence reflects data completeness, accounting quality, and model reliability. It is not a probability of future price.
Valuation drivers
- Normalized operating margin
- 37.1%
- Normalized NOPAT margin
- 29.9%
- Revenue growth
- 36.5%
- WACC
- 4.55%
- Terminal growth
- 2.50%
- Reinvestment method
- incremental roic
- Terminal-value share
- 93.5%
Model notes (4)
- Terminal value is 93% of enterprise value (Base case)
- Terminal value is 90% of enterprise value (Conservative case)
- Terminal value is 95% of enterprise value (Optimistic case)
- Minority interest not reported
Model details
- Normalization
- V1
- Scenario
- V2
- Confidence
- V1
- Engine version
- valuation-1.0.1-share-units-terminal
- Data snapshot
- filed:2026-02-17